vs
Amneal Pharmaceuticals, Inc.（AMRX）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是Amneal Pharmaceuticals, Inc.的1.8倍（$1.3B vs $722.5M），Amneal Pharmaceuticals, Inc.同比增速更快（3.9% vs -5.8%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（1.5% vs -6.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
AMRX vs RHI — 直观对比
营收规模更大
RHI
是对方的1.8倍
$722.5M
营收增速更快
AMRX
高出9.7%
-5.8%
两年增速更快
AMRX
近两年复合增速
-6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $1.3B |
| 净利润 | $78.0M | — |
| 毛利率 | 44.3% | 37.6% |
| 营业利润率 | — | 1.7% |
| 净利率 | 10.8% | — |
| 营收同比 | 3.9% | -5.8% |
| 净利润同比 | 217.0% | — |
| 每股收益（稀释后） | $0.19 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRHI
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $1.3B | ||
| Q3 25 | $784.5M | $1.4B | ||
| Q2 25 | $724.5M | $1.4B | ||
| Q1 25 | $695.4M | $1.4B | ||
| Q4 24 | $730.5M | $1.4B | ||
| Q3 24 | $702.5M | $1.5B | ||
| Q2 24 | $701.8M | $1.5B |
净利润AMRXRHI
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | $42.9M | ||
| Q2 25 | $22.4M | $41.0M | ||
| Q1 25 | $12.2M | $17.4M | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | $65.5M | ||
| Q2 24 | $6.0M | $68.2M |
毛利率AMRXRHI
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 37.6% | ||
| Q3 25 | 34.9% | 37.2% | ||
| Q2 25 | 39.5% | 37.2% | ||
| Q1 25 | 36.8% | 36.9% | ||
| Q4 24 | 36.0% | 38.8% | ||
| Q3 24 | 38.4% | 39.0% | ||
| Q2 24 | 35.6% | 39.2% |
营业利润率AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 1.7% | ||
| Q3 25 | 9.0% | 1.0% | ||
| Q2 25 | 15.4% | 0.1% | ||
| Q1 25 | 14.4% | 2.9% | ||
| Q4 24 | 10.4% | 4.7% | ||
| Q3 24 | 12.6% | 4.1% | ||
| Q2 24 | 13.6% | 5.1% |
净利率AMRXRHI
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | 3.2% | ||
| Q2 25 | 3.1% | 3.0% | ||
| Q1 25 | 1.8% | 1.3% | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | 4.5% | ||
| Q2 24 | 0.9% | 4.6% |
每股收益（稀释后）AMRXRHI
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.32 | ||
| Q3 25 | $0.01 | $0.43 | ||
| Q2 25 | $0.07 | $0.41 | ||
| Q1 25 | $0.04 | $0.17 | ||
| Q4 24 | $-0.10 | $0.53 | ||
| Q3 24 | $0.00 | $0.64 | ||
| Q2 24 | $0.02 | $0.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $1.3B |
| 总资产 | — | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $464.4M | ||
| Q3 25 | $201.2M | $365.3M | ||
| Q2 25 | $71.5M | $380.5M | ||
| Q1 25 | $59.2M | $342.5M | ||
| Q4 24 | $110.6M | $537.6M | ||
| Q3 24 | $74.0M | $570.5M | ||
| Q2 24 | $43.8M | $547.4M |
总债务AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $1.3B | ||
| Q3 25 | $-109.5M | $1.3B | ||
| Q2 25 | $-112.1M | $1.3B | ||
| Q1 25 | $-131.7M | $1.3B | ||
| Q4 24 | $-109.3M | $1.4B | ||
| Q3 24 | $-93.4M | $1.5B | ||
| Q2 24 | $-57.5M | $1.5B |
总资产AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $2.9B | ||
| Q3 25 | $3.6B | $2.8B | ||
| Q2 25 | $3.4B | $2.8B | ||
| Q1 25 | $3.4B | $2.7B | ||
| Q4 24 | $3.5B | $2.9B | ||
| Q3 24 | $3.5B | $3.0B | ||
| Q2 24 | $3.5B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.5M |
| 自由现金流经营现金流 - 资本支出 | — | $170.8M |
| 自由现金流率自由现金流/营收 | — | 13.1% |
| 资本支出强度资本支出/营收 | — | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $266.8M |
8季度趋势，按日历期对齐
经营现金流AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $182.5M | ||
| Q3 25 | $118.5M | $77.4M | ||
| Q2 25 | $83.8M | $119.4M | ||
| Q1 25 | $7.4M | $-59.3M | ||
| Q4 24 | $118.1M | $154.8M | ||
| Q3 24 | $141.8M | $129.6M | ||
| Q2 24 | $39.7M | $142.0M |
自由现金流AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $170.8M | ||
| Q3 25 | $106.2M | $63.6M | ||
| Q2 25 | $61.0M | $104.2M | ||
| Q1 25 | $-5.8M | $-71.7M | ||
| Q4 24 | $102.9M | $140.5M | ||
| Q3 24 | $124.8M | $111.8M | ||
| Q2 24 | $29.0M | $129.6M |
自由现金流率AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | 13.1% | ||
| Q3 25 | 13.5% | 4.7% | ||
| Q2 25 | 8.4% | 7.6% | ||
| Q1 25 | -0.8% | -5.3% | ||
| Q4 24 | 14.1% | 10.2% | ||
| Q3 24 | 17.8% | 7.6% | ||
| Q2 24 | 4.1% | 8.8% |
资本支出强度AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 0.9% | ||
| Q3 25 | 1.6% | 1.0% | ||
| Q2 25 | 3.2% | 1.1% | ||
| Q1 25 | 1.9% | 0.9% | ||
| Q4 24 | 2.1% | 1.0% | ||
| Q3 24 | 2.4% | 1.2% | ||
| Q2 24 | 1.5% | 0.8% |
现金转化率AMRXRHI
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | 1.80× | ||
| Q2 25 | 3.74× | 2.91× | ||
| Q1 25 | 0.61× | -3.42× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 6.62× | 2.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
